Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Acurx Pharmaceuticals, Inc. ACXP

Healthcare  —  Biotechnology
1.36 0.00 0.00% as of 25 Sep
Market cap
$7.6M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Acurx Pharmaceuticals, Inc. (ACXP) Business Profile

Updated before January 2025

Company Overview

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) is a clinical-stage biopharmaceutical company dedicated to developing new antibiotics for the treatment of bacterial infections. Founded in 2017 and headquartered in Staten Island, New York, Acurx focuses on addressing the growing global threat of antibiotic resistance. The company is led by a team of seasoned professionals with extensive experience in the pharmaceutical and biotechnology industries. Key leadership includes Robert J. DeLuccia, Co-Founder and Executive Chairman, and David P. Luci, Co-Founder, President, and CEO. Together, they bring a wealth of expertise in drug development, commercialization, and corporate strategy.

Core Business Segments

Acurx Pharmaceuticals operates primarily in the field of infectious disease treatment, with a focus on developing novel antibiotics. The company’s core business segments include:

1. Antibiotic Development

Acurx’s flagship product pipeline is centered around its DNA polymerase IIIC inhibitors, a novel class of antibiotics targeting Gram-positive bacterial infections. The lead product candidate, Ibezapolstat, is currently in clinical trials for the treatment of Clostridioides difficile infections (CDI). CDI is a serious and often life-threatening infection that affects the gastrointestinal tract, and Acurx aims to address this unmet medical need with its innovative approach.

2. Research and Development (R&D)

The company invests heavily in R&D to expand its pipeline of antibiotics. Acurx is exploring additional indications for its DNA polymerase IIIC inhibitors, including other Gram-positive bacterial infections. The company’s R&D efforts are supported by collaborations with academic institutions and research organizations.

Business Model

Acurx Pharmaceuticals operates as a clinical-stage biopharmaceutical company, meaning its primary focus is on the development and testing of new drug candidates rather than the commercialization of existing products. The company generates revenue through partnerships, licensing agreements, and potential future sales of its products once they receive regulatory approval. Acurx’s business model emphasizes:

  • Innovation: Developing first-in-class and best-in-class antibiotics to address unmet medical needs.
  • Collaboration: Partnering with academic institutions, research organizations, and other pharmaceutical companies to accelerate drug development.
  • Regulatory Milestones: Achieving key regulatory approvals to advance its product candidates through clinical trials and into the market.

Strategic Direction

Acurx Pharmaceuticals is committed to addressing the global health crisis posed by antibiotic resistance. The company’s strategic priorities include:

  • Advancing Clinical Trials: Completing Phase 2 and initiating Phase 3 clinical trials for Ibezapolstat.
  • Expanding the Pipeline: Developing additional DNA polymerase IIIC inhibitors for other Gram-positive bacterial infections.
  • Sustainability Goals: Promoting responsible antibiotic use and stewardship to minimize the development of resistance.
  • Global Reach: Exploring opportunities to expand its presence in international markets through partnerships and licensing agreements.

Competitive Landscape

Acurx Pharmaceuticals operates in a highly competitive market, facing competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Merck & Co., Inc.: A global leader in antibiotics and infectious disease treatments.
  • Pfizer Inc.: Known for its extensive portfolio of anti-infective drugs.
  • Paratek Pharmaceuticals, Inc.: Focused on developing novel antibiotics for serious bacterial infections.
  • Iterum Therapeutics plc: Specializing in antibiotics for multi-drug-resistant infections.

Despite the competition, Acurx differentiates itself through its innovative approach to antibiotic development and its focus on addressing unmet medical needs.

Risk Factors

Like any biopharmaceutical company, Acurx Pharmaceuticals faces several risks, including:

  • Regulatory Risks: Delays or failures in obtaining regulatory approvals for its product candidates.
  • Market Dependence: Reliance on the success of Ibezapolstat and other pipeline products.
  • Financial Risks: Limited revenue generation as a clinical-stage company, leading to dependence on external funding.
  • Supply Chain Disruptions: Potential challenges in sourcing raw materials and manufacturing clinical trial supplies.
  • Competitive Risks: Intense competition from larger, more established companies with greater resources.

Recent Developments

Acurx Pharmaceuticals has made significant progress in advancing its lead product candidate, Ibezapolstat. Recent developments include:

  • Clinical Trial Milestones: Successful completion of Phase 2a clinical trials for Ibezapolstat, demonstrating its safety and efficacy in treating CDI.
  • Regulatory Engagement: Ongoing discussions with the U.S. Food and Drug Administration (FDA) to design Phase 3 clinical trials.
  • Pipeline Expansion: Preclinical studies exploring additional indications for DNA polymerase IIIC inhibitors.
  • Corporate Strategy: Strengthening its leadership team and securing additional funding to support clinical development.

Investment Considerations

Investors considering Acurx Pharmaceuticals should weigh the following strengths and risks:

Strengths

  • Innovative Pipeline: Acurx’s focus on novel antibiotics addresses a critical unmet medical need.
  • Experienced Leadership: The management team has a proven track record in drug development and commercialization.
  • Market Opportunity: The growing threat of antibiotic resistance creates a significant demand for new treatments.

Risks

  • Clinical and Regulatory Uncertainty: The success of Acurx’s pipeline depends on the outcome of clinical trials and regulatory approvals.
  • Financial Dependence: As a clinical-stage company, Acurx relies on external funding to support its operations.
  • Market Competition: Intense competition from larger pharmaceutical companies could impact Acurx’s market share.

Conclusion

Acurx Pharmaceuticals, Inc. is well-positioned to address the global health crisis posed by antibiotic resistance. With its innovative pipeline, experienced leadership, and commitment to addressing unmet medical needs, the company has the potential for significant growth. However, investors should carefully consider the risks associated with clinical-stage biopharmaceutical companies. As Acurx advances its clinical trials and expands its pipeline, it remains a promising player in the fight against antibiotic resistance.